In the rat pineal, formation of the second messenger cyclic GMP (cGMP) is under adrenergic control. Two important sequential steps mediate adrenergic signal transduction by cGMP, receptor-stimulated nitric oxide (NO) formation by the enzyme NO synthase I (NOS I), and NO-induced cGMP formation by the cytosolic enzyme guanylyl cyclase. With regard to the first step in cGMP transduction (i.e. NO formation) we found, by means of NOS I immunostaining and NADPH-diaphorase staining, that the presence of NOS I was restricted to a subpopulation of pineal cells, generally surrounded by NOS I-negative cells. Considering the fact that NO is able to permeate the cell membrane, the question arises whether the second step in cGMP signalling (i.e. NO-induced cGMP formation) is restricted to the NO-forming cell itself or takes place in neighboring cells as well. It was found that oxyhemoglobin, which scavenges NO but does not enter cells, strongly decreased adrenergic cGMP response. This suggests that a considerable part of adrenergically induced NO stimulates cGMP formation in neighboring cells. Our findings indicate that in the rat pineal the components of adrenergic cGMP transduction are largely distributed among two types of cells: NOS I-containing pineal cells where adrenoceptor stimulation induces NO formation, and neighboring cells in which NO stimulates cGMP formation.

Keywords:
Pineal gland, Nitric oxide, Cyclic GMP, Catecholamines
1.
O’Dea RF, Zatz M: Catecholamine stimulated cGMP accumulation in the rat pineal: Apparent presynaptic site of action. Biochemistry 1976;73:3398–3402.
2.
Klein DC, Auerbach DA, Weller JL: Seesaw signal processing in pineal cells: Homologous sensitization of adrenergic stimulation of cyclic GMP accompanies homologous desensitization of β-adrenergic stimulation of cAMP. Proc Natl Acad Sci USA 1981;78:4625–4629.
3.
Sugden D: β-Adrenergic regulation of cyclic GMP in rat pinealocytes. Biochem Biophys Res Commun 1990;167:835–841.
4.
Vanecek J, Sugden D, Weller JL, Klein DC: Atypical synergistic α1- and β-adrenergic regulation of adenosine 3′,5′-monophosphate and guanosine 3′,5′-monophosphate in rat pinealocytes. Endocrinology 1985;116:2167–2173.
5.
Chik CL, Liu QY, Bing L, Karpinski E, Ho AK: cGMP inhibits L-type Ca2+ channel currents through protein phosporylation in rat pinealocytes. J Neurosci 1995;15:3104–3109.
6.
Yamada H, Yamamoto A, Takahashi M, Michibata H, Kumon H, Moriyama Y: The L-type Ca2+ channel is involved in microvesicle-mediated glutamate exocytosis from rat pinealocytes. J Pineal Res 1996;21:165–174.
7.
Lin AMY, Schaad NC, Schulz PE, Coon SL, Klein DC: Pineal nitric oxide synthase: Characteristics, adrenergic regulation and function. Brain Res 1994;651:160–168.
8.
Schaad NC, Vanecek J, Schulz PE: Photoneural regulation of rat pineal nitric oxide synthase. J Neurochem 1994;62:2496–2499.
9.
Spessert R, Layes E, Vollrath L: Adrenergic stimulation of cGMP formation requires NO-dependent activation of cytosolic guanylate cyclase in rat pinealocytes. J Neurochem 1993;61:138–143.
10.
Bredt DS, Snyder SH: Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 1990;87:682–685.
11.
Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;277:680–688.
12.
Alm P, Larsson B, Ekblad E, Sundler F, Andersson K-E: Immunohistochemical localization of peripheral nitric oxide synthase-containing nerves using antibodies raised against C- and N-terminal fragments of a cloned enzyme from rat brain. Acta Physiol Scand 1993;148:421–429.
13.
Murphy ME, Noack E: Nitric oxide assay using hemoglobin method. Meth Enzymol 1994;233:240–250.
14.
Spessert R, Vollrath L: Muscarinic agonists have no measurable effect on cGMP formation of rat pinealocytes. Brain Res Bull 1993;32:589–592.
15.
Kimura H, Murad F: Non enzymatic formation of guanosine 3′,5′-monophosphate from guanosine triphosphate. J Biol Chem 1974;249:329–331.
16.
Harper JF, Brooker G: Femtomol sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 2′O acetylation by acetic anhydride in aqueous solution. J Cyclic Nucleotide Res 1975;1:207–218.
17.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265–271.
18.
Loepz-Figueroa MO, Moller M: Localization of NADPH-diaphorase in the rat pineal gland: An experimental enzyme histochemical study. J Pineal Res 1996;20:157–163.
19.
Vollrath L, Schmidt DS: Enzymhistochemische Untersuchungen an der Zirbeldrüse normaler und trächtiger Meerschweinchen. Histochemie 1969;20:328–337.
20.
Beesley JE: Histochemical methods for detecting nitric oxide synthase. Histochem J 1995;27:757–769.
21.
Blottner D, Grozdanovic Z, Gossrau R: Histochemistry of nitric oxide synthase in the nervous system. Histochem J 1995;27:785–811.
22.
Spessert R, Layes E, Schollmayer A, Reuss S, Vollrath L: In the rat pineal gland, but not in the suprachiasmatic nucleus, the amount of constitutive neuronal nitric oxide synthase is regulated by environmental lighting conditions. Biochem Biophys Res Commun 1995;212:70–76.
23.
Layes E, Schollmayer A, Spessert R, Vollrath L: Expression of brain nitric oxide synthase in the developing rat pineal gland coincides with the appearance of the adrenergic cyclic guanosine 3′,5′-monophosphate response. Neurosci Lett 1996;212:71–73.
24.
Schaad NC, Parfitt A, Rusell JT, Schaffner AE, Korf HW, Klein DC: Single cell [Ca2+]i analysis and biochemical characterization of pinealocytes immobilized with novel attachment peptide preparation. Brain Res 1993;614:251–256.
25.
Schomerus C, Laedtke E, Korf HW: Calcium responses of isolated, immunocytochemically identified rat pinealocytes to noradrenergic, cholinergic and vasopressinergic stimulations. Neurochem Int 1995;27:163–175.
26.
Spessert R: Vasoactive intestinal peptide stimulation of cyclic guanosine monophosphate formation: Further evidence for a role of nitric oxide synthase and cytosolic guanylate cyclase in rat pinealocytes. Endocrinology 1993;132:2513–2517.
27.
Lancaster JR: Stimulation of the diffusion and reaction of endogenously produced nitric oxide. Proc Natl Acad Sci USA 1994;91:8137–8141.
28.
Lancaster JR: Diffusion of free nitric oxide. Meth Enzymol 1996;268:31–50.
29.
Garthwaite J: Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci 1991;14:60–67.
30.
Hu J, El-Fakahany EE: Role of intercellular and intracellular communication by nitric oxide in coupling of muscarinic receptors to activation of guanylate cyclase in neuronal cells. J Neurochem 1993;61:578–585.
31.
Malcolm C, Grieve A, Ritchie L, Schousboe A, Griffiths R: NMDA receptor-mediated cyclic GMP-synthesis in primary cultures of mouse cerebellar granule cells appears to involve neuron-astrocyte communication with NO operating as the intercellular messenger. J Neurosci Res 1996;45:129–142.
32.
Southam E, Garthwaite J: The nitric oxide-cyclic GMP signalling pathway in the brain. Neuropharmacology 1993;32:1267–1277.
33.
Spessert R, Hill G, Vollrath L: In rat pinealocytes the cyclic cGMP response to NO is regulated by Ca2+ and protein kinase C. Brain Res 1995;694:207–212.
34.
White BH, Klein DC: Stimulation of cyclic GMP accumulation by sodium nitroprusside is potentiated via a Gs mechanism in intact pinealocytes. J Neurochem 1995;64:711–717.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.